Cypre Status
The company raised $150,000 of convertible debt funding from undisclosed investors on August 24, 2018. Earlier, the company raised an undisclosed amount of venture funding from Hemi Ventures on January 1, 2017.
Developer of a tumor microenvironment system intended to be used for the transformative 3D cellular research and clinical testing of cancer patients. The company's tumor microenvironment system consists of extracellular matrix remodeling, immune infiltration and other processes that influence tumor progression, enabling medical institutions with better and advanced drugs, opening the door for a new generation of therapeutics and patient success.
Year Founded
2016
General Information
-
Website
-
Business Status
Generating Revenue
-
Ownership Status
Privately Held (backing)
-
Financing Status
Venture Capital-Backed
Cypre News and Updates
Global exploration and production
Offshore Oil and Gas Magazine | January 16, 2020
Booked on the Bayou: Police report for Dec. 14-16, 2019
Houma Courier | December 17, 2019
Deepwater Investments to Grow Above 5% in 2020
Offshore Engineer | December 15, 2019
Aker Solutions wins BP Cypre FEED study
WorldOil | December 11, 2019
Aker Solutions Wins BP Cypre Front-End Study
BNamericas English | December 10, 2019
Aker Solutions wins Cypre FEED
Upstream Online | December 10, 2019
Cypre's Verticals
Cypre Primary Industry Sector / Group / Code
Cypre's Trends
Cypre Metrics
Majestic Referring Domains
Headquarters
-
HQ Address Line 1953 Indiana Street
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ Post Code94107
-
HQ CountryUnited States
Cypre's Keywords
mood_badFeed is empty.
Add a review